Magellan Pharmaceutical Development Appoints VP

Pharmaceutical Development Organization Hires New Business Development Leader

RESEARCH TRIANGLE PARK, N.C. (June 5, 2002)) - Magellan Pharmaceutical Development, a full-service contract pharmaceutical development organization (PDO) formerly known as Magellan Laboratories and now owned by Cardinal Health, named Lori Feehan vice president of business development.

Feehan, who is based out of Magellan's new Somerset, N.J. facility, will lead the sales groups for Somerset, Research Triangle Park, N.C. and Albuquerque, N.M. By fully leveraging Magellan's capabilities with Cardinal Health and vice versa, Feehan will be able to identify and capture opportunities for clients requiring the full spectrum of drug development services.

During the past year, Feehan served under Cardinal Health's Pharmaceutical Technologies & Services Commercial Development (PTSC) group as vice president and project consultant. Feehan collaborated with the Pharmaceutical Technologies & Services (PTS) business units and account development team to secure formulation and development agreements.

Prior to Cardinal, Feehan was with Pfizer/Warner-Lambert as vice president and general manager of North America Schick®. She was also the vice president, global category director of Upper Respiratory brands, where she was involved in accessing Phase I/II prescription compounds for in-licensing.

"Lori's history leading large-scale sales efforts and her familiarity with Cardinal's PTSC group makes her the ideal candidate for this senior position," says Lowry Caudill, president of pharmaceutical development at Magellan. "We are confident that Lori will continue to build the company as the premiere provider of outsourced pharmaceutical and biopharmaceutical product development."

Feehan earned her bachelor's degree in economics and American studies at Douglass College and her M.B.A. in marketing/finance at Rutgers University.

About Magellan Pharmaceutical Development

Founded in 1991 by leading pharmaceutical scientists and formerly known as Magellan Laboratories, Magellan Pharmaceutical Development serves the continually changing needs of the pharmaceutical and biotechnological industries by providing a complete range of GLP/GMP compliant analytical testing and development services. Magellan's client roster lists about 200 active contractors, including nine of the top 10 pharmaceutical companies.

Magellan's recent acquisition by Cardinal Health creates the most comprehensive pharmaceutical development service provider to the pharmaceutical and biotechnology industries, from early stage drug development to commercial manufacturing for virtually every dosage form.

Magellan features seven strategic divisions: Analytical, Inhalation, Microbiology, Structural Chemistry, Synthesis, Research & Bioanalytical and Pharmaceutics. Magellan is based in Research Triangle Park, N.C., with a biotech facility in San Diego, Calif. and a pharmaceutical development facility in Albuquerque, N.M. For more information on Magellan Pharmaceutical Development, visit www.magellanlabs.com.